Article

Studies implicate photoreceptor mitochondria as initiator in uveitis-associated vision loss

Mitochondrial oxidative stress induced by translocation of inducible nitric oxide synthetase (iNOS) from the cytosol into the photoreceptor mitochondria appears to be a primary event leading to photoreceptor damage in experimental autoimmune uveitis (EAU), said Narsing A. Rao, MD, professor of ophthalmology, and director, ophthalmic pathology laboratory and uveitis service, University of Southern California, Los Angeles.

Mitochondrial oxidative stress induced by translocation of inducible nitric oxide synthetase (iNOS) from the cytosol into the photoreceptor mitochondria appears to be a primary event leading to photoreceptor damage in experimental autoimmune uveitis (EAU), said Narsing A. Rao, MD, professor of ophthalmology, and director, ophthalmic pathology laboratory and uveitis service, University of Southern California, Los Angeles.

"Epidemiologic studies show that complications of uveitis, particularly photoreceptor degeneration, are an important cause of vision loss," said Dr. Rao, who spoke during a symposium on mitochondrial oxidative stress in the visual system. "Based on previous investigations in EAU, the photoreceptor damage was thought to be caused by infiltrating macrophages releasing damaging oxidants.

"However, contradicting that dogma, we previously showed evidence that photoreceptor mitochondrial stress was present several days prior to infiltration of the phagocytic cells," Dr. Rao said. "Further studies now support the concept that the photoreceptor mitochondria are responsible for initiating the irreversible retinal damage occurring in EAU."

EAU, an animal model of uveitis that closely mimics the human disease, is created by immunizing Lewis rats with retinal soluble protein S-antigen. Dr. Rao described the findings from a series of EAU studies using wild type and iNOS knockout animals that were performed to characterize the cellular and molecular events occurring early after immunization.

Based on those experiments, Dr. Rao and colleagues proposed the following sequence to describe the pathway leading to photoreceptor damage in EAU.

"We believe that following immunization with the retinal antigen, a few activated T-cells infiltrate the retina where they induce expression of the TNF-alpha receptor and generate increases in TNF-alpha and other cytokines known to increase iNOS," Dr. Rao explained. "The upregulated iNOS subsequently translocates to the photoreceptor mitochondria and leads to mitochondrial oxidative stress and damage, including protein nitration, lipid peroxidation, and DNA damage, that ultimately culminates in photoreceptor cell apoptosis and vision loss."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.